These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9802333)

  • 1. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: relationship to drug lipophilicity and serum albumin binding.
    Demant EJ; Friche E
    Biochem Pharmacol; 1998 Nov; 56(9):1209-17. PubMed ID: 9802333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
    Friche E; Danks MK; Beck WT
    Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration.
    Demant EJ; Friche E
    Biochem Pharmacol; 1998 Jan; 55(1):27-32. PubMed ID: 9413926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
    Friche E; Demant EJ; Sehested M; Nissen NI
    Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
    Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of chemosensitizers on resistance mechanisms in daunorubicin-resistant Ehrlich ascites tumour cells.
    Nielsen D; Eriksen J; Maare C; Friche E; Skovsgaard T
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):453-60. PubMed ID: 12107549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.
    Friche E; Jensen PB; Roed H; Skovsgaard T; Nissen NI
    Biochem Pharmacol; 1990 Jun; 39(11):1721-6. PubMed ID: 2344368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for computer simulation of P-glycoprotein and transmembrane delta pH-mediated anthracycline transport in multidrug-resistant tumor cells.
    Demant EJ; Sehested M; Jensen PB
    Biochim Biophys Acta; 1990 Nov; 1055(2):117-25. PubMed ID: 2242381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone.
    Nielsen D; Eriksen J; Maare C; Litman T; Kjaersgaard E; Plesner T; Friche E; Skovsgaard T
    Biochem Pharmacol; 2000 Aug; 60(3):363-70. PubMed ID: 10856431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative serum protein binding of anthracycline derivatives.
    Chassany O; Urien S; Claudepierre P; Bastian G; Tillement JP
    Cancer Chemother Pharmacol; 1996; 38(6):571-3. PubMed ID: 8823501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes.
    Bouchelouche P; Friche E; Sehested M; Jensen PB; Skovsgaard T
    Biochem Pharmacol; 1991 Jan; 41(2):243-53. PubMed ID: 1899193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
    Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
    Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells.
    Sehested M; Bindslev N; Demant EJ; Skovsgaard T; Jensen PB
    Biochem Pharmacol; 1989 Sep; 38(18):3017-27. PubMed ID: 2571333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.
    Sehested M; Skovsgaard T; Jensen PB; Demant EJ; Friche E; Bindslev N
    Br J Cancer; 1990 Jul; 62(1):37-41. PubMed ID: 1975202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.
    Nielsen D; Maare C; Skovsgaard T
    Biochem Pharmacol; 1995 Aug; 50(4):443-50. PubMed ID: 7646548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells.
    Praet M; Stryckmans P; Ruysschaert JM
    Biochem Pharmacol; 1996 May; 51(10):1341-8. PubMed ID: 8787550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH regulation in sensitive and multidrug resistant Ehrlich ascites tumor cells.
    Litman T; Pedersen SF; Kramhøft B; Skovsgaard T; Hoffmann EK
    Cell Physiol Biochem; 1998; 8(3):138-50. PubMed ID: 9617476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of VP-16 to the classical multidrug resistance phenotype.
    Sehested M; Friche E; Jensen PB; Demant EJ
    Cancer Res; 1992 May; 52(10):2874-9. PubMed ID: 1581902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.